Redwire to manage NASA’s space microalgae experiment

Published 10/06/2025, 12:44
Redwire to manage NASA’s space microalgae experiment

JACKSONVILLE, Fla. - Redwire Corporation (NYSE:RDW), a $1.42 billion market cap company specializing in space infrastructure, has been selected by NASA to oversee a pioneering space microalgae biotechnology experiment. The company’s stock has shown remarkable momentum, surging over 216% in the past year. According to InvestingPro analysis, Redwire appears slightly overvalued at current levels, though analysts maintain positive growth expectations. The experiment, which is a collaborative project involving the Indian Space Research Organization (ISRO), the International Centre for Genetic Engineering and Biotechnology (ICGEB), and the National Institute of Plant Genome Research (NIPGR), is set to be conducted on the International Space Station (ISS).

The research will focus on examining the effects of microgravity on the growth, metabolism, and genetic expression of three strains of edible microalgae. These microorganisms are being studied as a potential sustainable food source for astronauts on extended space missions. Redwire’s role will encompass mission integration, scientific fulfillment, and operational management on orbit. With annual revenues of $277.7 million and analysts forecasting sales growth this year, the company is well-positioned to execute on this contract. For detailed financial analysis and growth projections, investors can access the comprehensive Pro Research Report available on InvestingPro.

John Vellinger, President of In-Space Industries at Redwire, expressed the company’s enthusiasm for collaborating with NASA and the international partners on this research that could significantly benefit long-term space exploration to destinations like the Moon and Mars.

Dr. Shashi Kumar from the ICGEB highlighted the importance of this investigation for advancing knowledge on microalgae as a nutritional supplement for space crews. He also noted that this initiative is the first space project supported under the Government of India’s BioE3 policy, which emphasizes biotechnology’s role in the economy, environment, and employment.

Redwire is recognized for its expertise in microgravity research and development technologies, with a focus on space biotechnology, pharmaceutical development, and plant research. The company boasts over three decades of experience in human spaceflight and operates multiple payloads and facilities on the ISS. InvestingPro data reveals the company operates with a moderate level of debt and is expected to achieve profitability this year, with analysts maintaining a strong buy consensus. InvestingPro subscribers have access to 15+ additional exclusive insights about Redwire’s financial health and growth prospects.

The upcoming Axiom Mission 4 (Ax-4) will carry an international crew from India, Poland, Hungary, and the United States to the ISS. This mission will mark the second human spaceflight for India, Poland, and Hungary and the first time these nations will conduct an investigation on the ISS.

The information in this article is based on a press release statement from Redwire Corporation.

In other recent news, Redwire Corporation has announced a revised agreement to acquire Edge Autonomy for $925 million, comprising $160 million in cash and $765 million in Redwire common stock. This acquisition awaits stockholder approval and is expected to enhance Redwire’s space infrastructure portfolio. Additionally, Redwire’s Mason technology, designed for lunar and Martian construction, successfully completed a Critical Design Review with NASA, marking a significant milestone in its development. The Mason project, part of a $12.9 million award under NASA’s Tipping Point agreement, aims to facilitate sustainable operations on extraterrestrial surfaces.

In another development, Redwire secured a contract to support Aspera Biomedicines in space-based cancer research using its Pharmaceutical In-space Laboratory (PIL-BOX) technology. This mission will focus on the development of rebecsinib, a cancer therapy targeting stem cells. Furthermore, Redwire successfully delivered the onboard computer for the European Space Agency’s Comet Interceptor mission, reinforcing its role in high-profile space missions. This achievement highlights Redwire’s avionics expertise and 25-year flight heritage.

Investors have shown confidence in Redwire’s recent advancements, as seen in the positive stock movement following these announcements. The company’s strategic moves and technological contributions continue to bolster its position in the space industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.